RxDoctor Payments Data

Malia Keen, APRN

Nurse Practitioner · Vero Beach, FLNPI 1780294298

Payments from drug & device makers

$19,054in general payments, 2019–2025

Across 860 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Johnson & Johnson$2K
  • Merck$1K
  • AstraZeneca$1K
  • Bristol Myers Squibb$876
  • Pfizer$819
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$17,14290%
  • Education$4973%
  • Other$1,4157%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis72$2,553
Johnson & Johnson(2 entities)84$1,779
Merck59$1,196
AstraZeneca(2 entities)51$1,135
Bristol Myers Squibb55$876
Pfizer52$819
Sanofi22$646
Seagen Inc.22$539
Bayer31$530
AbbVie23$488
E.r. Squibb & Sons, L.L.C.15$488
GSK23$474
Lilly USA, LLC20$450
Eisai Inc.20$432
Astellas Pharma US Inc19$420
Incyte Corporation19$411
Daiichi Sankyo Inc.16$379
Beigene USA, Inc.18$334
Amgen19$332
Ipsen Biopharmaceuticals, Inc14$327
Pharmacyclics LLC, An Abbvie Company14$322
Jazz Pharmaceuticals Inc.18$293
EMD Serono, Inc.11$276
Takeda Pharmaceuticals U.S.A., Inc.9$264
Regeneron Healthcare Solutions, Inc.14$263
Array Biopharma Inc15$251
Sobi, Inc9$240
Gilead9$216
Stemline Therapeutics Inc.8$197
Pharmacosmos Therapeutics Inc.8$179
Servier Pharmaceuticals LLC6$162
Beone Medicines USA, Inc.5$111
Pharmaessentia USA Corporation4$96
Sanofi-aventis U.S. LLC1$91
Karyopharm Therapeutics Inc.5$83
Puma Biotechnology, Inc.5$82
Taiho Oncology, Inc.4$78
Myovant Sciences Inc.4$70
AVEO Pharmaceuticals, Inc.3$69
Foundation Medicine, Inc.3$68
Rigel Pharmaceuticals, Inc.3$66
Tersera Therapeutics LLC2$66
Genentech USA, Inc.3$58
Legend Biotech USA Inc.3$57
Myriad Genetic Laboratories, Inc.3$53
Geron Corporation2$48
Biocon Biologics Inc2$46
Morphosys, US Inc.3$46
EUSA Pharma (US) LLC2$44
Mirati Therapeutics, Inc.2$44
Alnylam Pharmaceuticals Inc.2$42
Exelixis Inc.2$41
ADC Therapeutics America, Inc.2$40
AMAG Pharmaceuticals, Inc.2$38
Dendreon Pharmaceuticals LLC1$29
Dova Pharmaceuticals2$27
Blueprint Medicines Corporation1$27
Adaptive Biotechnologies Corporation1$26
Azurity Pharmaceuticals, Inc.1$25
Boehringer Ingelheim1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,054 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$32,512
Medicare patients
18
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate15$232,055
RevlimidLenalidomide13$204,515
LynparzaOlaparib12$182,394
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5018$148,910
EliquisApixaban55$41,561
XareltoRivaroxaban14$20,420
Fondaparinux Sodium11$19,578
Exemestane12$2,483
Anastrozole97$1,659
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl11$1,403
Letrozole66$1,345
Ondansetron Hcl81$946
Dexamethasone33$681
Acyclovir48$649
Hydroxyurea25$599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Lynparza$1,135$414,44927 claims
Bristol Myers SquibbRevlimid$876$204,51513 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$264$148,91018 claims
PfizerEliquis$819$41,56155 claims
Johnson & JohnsonXarelto$1,779$20,42014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →